Erratum

Fertility and sterility · 2020 · vol. 113(1) , pp. 237 · doi:10.1016/j.fertnstert.2019.10.032 · PMID:32033720 · W4230296075
Other OA: hybrid CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-12 ⓘ

This erratum corrects the disclosure statement for author A.M.S. in a prior publication regarding the impact of elagolix on work loss due to endometriosis-associated pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In the article by Pokrzywinski, et al., “Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials” (Fertil Steril 2019;112:545-51), author Soliman’s disclosures were incorrectly listed. They should read A.M.S. is an employee of and owns stock/stock options in AbbVie.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:26:40.963384+00:00
License: CC0 · commercial use OK